These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18851761)

  • 21. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
    HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
    Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    Taylor S; van Heeswijk RP; Hoetelmans RM; Workman J; Drake SM; White DJ; Pillay D
    AIDS; 2000 Sep; 14(13):1979-84. PubMed ID: 10997403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
    Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
    van Leth F; Huisamen CB; Badaro R; Vandercam B; de Wet J; Montaner JS; Hall DB; Wit FW; Lange JM;
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):296-300. PubMed ID: 15735447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A; Saleri N; Villani P; Bonkoungou V; Carvalho AC; Kouanda S; Sanou MJ; Simporé J; Monno L; Carosi G; Regazzi M; Dembele M
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):64-9. PubMed ID: 19731452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
    Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P;
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
    JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
    Yozviak JL; Doerfler RE; Woodward WC
    HIV Clin Trials; 2001; 2(6):474-6. PubMed ID: 11742435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM;
    AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Chantratitra W
    AIDS Patient Care STDS; 2007 Oct; 21(10):711-4. PubMed ID: 17949267
    [No Abstract]   [Full Text] [Related]  

  • 39. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.